Here is Why Eli Lilly (LLY) is One of the Best Stocks to Buy for the Next 15 Years

Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for the next 15 years. On May 7, Eli Lilly executed its largest bond issuance to date, selling $9 billion in investment-grade debt to fund a recent surge in acquisitions. The offering, which initially targeted $8 billion, saw high investor demand following a credit rating upgrade by S&P Global Ratings and a favorable market environment.

The sale consisted of eight tranches with maturities spanning 2 to 40 years, with the longest-term bonds yielding 0.8 percentage points above Treasuries. The proceeds are earmarked for general corporate purposes and the financing of two major deals totaling nearly $15 billion: the $7.8 billion acquisition of sleep-drug producer Centessa Pharmaceuticals Plc and the $7 billion purchase of cancer-drug developer Kelonia Therapeutics.

Canaccord Maintains Buy Rating on Compass Therapeutics (CMPX)

Notably, the terms include a provision where Eli Lilly and Company (NYSE:LLY) must repurchase certain notes at 101 cents on the dollar if the Centessa transaction fails to close. This capital raise follows a strong first-quarter performance and increased 2026 guidance driven by high demand for the company’s weight-loss medications.

Eli Lilly and Company (NYSE:LLY) is a healthcare company that develops human pharmaceutical products, including cardiometabolic health, oncology, and immunology products.

While we acknowledge the risk and potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LLY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.